NanoLIPID™ - Innovative Lipid Systems for Enhanced Bioavailability of Drugs: Preclinical Proof of Concept

Important results from the project

The project has successfully achieved all three main objectives. A novel, stable lipid-based formulation of semaglutide was developed and evaluated in vitro. A pilot study in vivo confirmed the tolerability and pharmacokinetics of oral delivery with the NanoLIPID™ technology. The results validate the platform, reduce the technical risk and strengthen the company´s commercial position in the dialogue with investors and industrial partners.

Expected long term effects

The project´s results are expected to enable oral alternatives to injectable drugs, reducing single-use medical waste such as needles and syringes. The green enzyme technology also provides a sustainable manufacturing process with low environmental impact and minimal waste. The in vivo validation of the NanoLIPID™ platform crosses a critical commercial threshold, laying the foundation for future licensing agreements, international industrial collaborations and continued growth of the company.

Approach and implementation

The project followed a logical sequence: formulation, in vitro testing and an in vivo pilot study of pharmacokinetics and tolerability. Minor delays occurred due to the complexity of the animal studies and late deliveries, but were resolved quickly. The collaboration worked excellently, with regular physical meetings being a key success factor. The strong results strengthened investor confidence and contributed to our investment round in 2026.